COVID-19 & Ukraine War Underpin EU Moves To Secure Medicines Supply
Executive Summary
Concerns by the drug industry over “complex and burdensome” regulatory requirements regarding security of supply could be addressed in the upcoming revision of the EU pharmaceutical legislation, suggests a report on the European Commission’s “structured dialog” process for tackling medicine supply chain vulnerabilities.
You may also be interested in...
Slew Of Challenges Calls For Revised Biopharma Playbook
While not immune to the impact of a storm of macroeconomic pressures, pharma companies have pulled through before, and they’ll do it again. However, this time around, the economic, geopolitical and internal cost and revenue pressures are unique and weathering the near-term turbulence will call for smart investment strategies that not only focus on quality assets, but that update companies to take advantage of new digital opportunities.
Building The Pharma Supply Chain Of The Future
The worst of COVID-19’s disruption appears to be in the pharma supply chain’s rearview mirror, but logistics stakeholders still have a number of questions to answer and challenges to overcome as they attempt to become future-proof.
Jan Deadline For API QR Codes In India Arrives; Are Local, Chinese Firms Prepared?
Beginning January, packaging on active pharmaceutical ingredients (APIs) made in or imported into India is to bear a QR code, but the Indian industry is unprepared and feels the move isn’t beneficial. With about 70% of the country’s API imports coming from China, questions remain on its implementation too